United States

AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

27 May 2016
Change (% chg)

$0.09 (+2.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AEZS.O


Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS... (more)


Beta: 1.76
Market Cap(Mil.): $34.74
Shares Outstanding(Mil.): 9.94
Dividend: --
Yield (%): --


  AEZS.O Industry Sector
P/E (TTM): -- 43.43 35.28
EPS (TTM): -22.23 -- --
ROI: -90.63 -5.58 13.31
ROE: -241.39 -5.65 14.56

BRIEF-Aeterna Zentaris acquires U.S. Promotional rights for prostate cancer blood test

* Aeterna zentaris acquires exclusive u.s. Promotional rights for apifiny prostate cancer blood test Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 27 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Ford Investor Services, Inc.
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.